Associate Professor Dr June Choon Wai Yee

Associate Professor Dr June Choon Wai Yee

  • Head of School
  • Associate Professor
  • School of Pharmacy
Faculty of Medical and Life Sciences
SDGs Focus

Biography


Associate Professor Dr June Choon is a Malaysian registered pharmacist with over a decade of experience across academia and industry. Trained in Pharmaceutical Technology and subsequently in Health Economics, she has taught pharmacy programmes across Cardiff University, Monash University, and Universiti Teknologi MARA (UiTM). 

As a subject-matter expert, she serves as an external consultant to the Ministry of Health’s Pharmaceutical Services Programme and the National Pharmaceutical Regulatory Agency (NPRA), and sits on various national-level committees including the Steering Committee of the 4th National Medicines Policy (Dasar Ubat Nasional, DUNas 2022–2026), the MOH Technical Committee for the Pharmaceutical Research Cluster and National Clinical Research Committee (Jawatankuasa Penyelidikan Klinikal Kebangsaan, JPKK, 2023). 

In collaboration with multinational pharmaceutical companies, her portfolio; spanning cost-effectiveness analyses, budget-impact assessments, and real-world evidence generation, her research informs medicine listing into the MOH Formulary decisions, and has direct impact on patient access to innovative medicines in the public healthcare system. Her tenure as Scientific Advisor to the Pharmaceutical Association of Malaysia (PhAMA) and as a consultant to the Ministry of Health Malaysia and multinational companies has deepened her understanding of real-world healthcare challenges, enabling her to bridge theory and practice with agility. 
 

Academic & Professional Qualifications

  • PhD, Universiti Sains Malaysia (2013)
  • BPharm(Hons), Universiti Sains Malaysia, 2006
  • Certificate in Higher Education Teaching and Learning (HETL), Universiti Teknologi MARA

Research Interests

  • Health Economics and Outcomes Research
  • Medicines Policy

Teaching Areas

  • Health Economics
  • Research Methodology
  • Pharmacokinetics
  • Pharmaceutical Technology

Courses Taught

  • Health Economics
  • Research Methodology
  • Pharmacokinetics
  • Dosage Form Design

Notable Publications

  1. Surgical site infection following colorectal surgeries: Incidence, healthcare resource utilisation and risk factors in a major referral hospital in Malaysia.
    Lee, Kenneth Kwing Chin et al. Clinical Epidemiology and Global Health, Volume 35, 102167, Sept – Oct, 2025.   https://www.ceghonline.com/article/S2213-3984(25)00257-X/fulltext
  2. Difference in healthcare resource utilization and health-related quality of life between patients with major depressive disorder (MDD) and treatment-resistant depression (TRD) in a public hospital in Malaysia – a retrospective case-note review and cross-sectional survey.  Lee, K. K. C., Mohamed, N. N. E., Abdul Aziz, S., Mohamad Nazri, D., Abdul Malek, A. Z., Lim, J. S., … Sellappans, R. (2025). Expert Opinion on Pharmacotherapy, 26(5), 653–662. https://doi.org/10.1080/14656566.2025.2472976
  3. Cost-Effectiveness of Rivaroxaban Compared with Other Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation in Public Sector of Malaysia. Lee, K.K., Zheng, C., Lim, J., & Choon, J. (2024). International Journal of Health Economics and Policy (Volume 9, Issue 1).  https://www.sciencepublishinggroup.com/article/10.11648/j.hep.20240901.12
  4. Frontiers in Pharmacology: Increasing Importance of Patients-Generated Real-World Data for Healthcare Policy Decisions About Medicinal Products. Kenneth KC Lee, Wai Yee Choon, Chee Jen Cheng, Jeff Guo and Paul Scuffham. April 2022. 
    https://www.frontiersin.org/research-topics/17794/increasing-importance-of-patients-generated-real-world-data-for-healthcare-policy-decisions-about-medicinal-products/magazine
  5. Stakeholders’ Views on Patient Access Schemes in Malaysia. Value in Health Regional Issues Volume 31, September 2022, Pages 39-46. Health Policy Analysis. Subramaniam Thanimalai, Wai Yee Choon, Kenneth Lee. https://www.sciencedirect.com/science/article/abs/pii/S2212109922000966
  6. Stakeholder Views of Managed Entry Agreements: A Literature Review of National Studies. Subramaniam T, Choon WY, Kenneth KC Lee. Health Policy OPEN, Volume 2, January 2021. https://www.sciencedirect.com/science/article/pii/S2590229621000034
  7. Is Dual-Policy an Overarching Strategy for Medicine Price Controls in Malaysia? June Choon, Kenneth Lee. Letter to editor. Asia Pacific Journal of Public Health. January 2020. https://pubmed.ncbi.nlm.nih.gov/32500785/
  8. Real-world evidence of improved healthcare utilisation in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong. Choon WY, Wu DB, Chong HY, Lo WT, Chong CS, Chung WS, Chui EM, Tomlinson B, Lee VW, Lee SC, Lee KK. Journal of Medical Economics, J Med Econ. 2019 Mar;22(3):273-279. doi:10.1080/13696998.2018.1560749. Epub 2019 Jan 14. PMID: 30561238, presented at the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific, Tokyo, Japan, 2018. https://pubmed.ncbi.nlm.nih.gov/30561238/

Achievements & Accolades

  1. Joint Industry Study: Implementation of E-Labelling of Pharmaceutical Products in Malaysia. 
    In collaboration with the National Pharmaceutical Regulatory Agency (Ministry of Health Malaysia).
    Supported by the Pharmaceutical Association of Malaysia (PhAMA), Malaysian Organisation of Pharmaceutical Industries (MOPI) and Malaysian Association of Pharmaceutical Suppliers (MAPS).
  2. Economic costs of Spinal Muscular Atrophy (SMA) in Malaysia from a Societal Perspective. 
    Supported by Roche (Malaysia) and in collaboration with Spinal Muscular Atrophy Malaysia (SMAM).
  3. Surgical site infection following colorectal surgeries: Incidence, healthcare resource utilisation and risk factors in a major referral hospital in Malaysia. 
    Supported by Johnson & Johnson (Malaysia).
  4. Difference in healthcare resource utilization and health-related quality of life between patients with major depressive disorder (MDD) and treatment-resistant depression (TRD) in a public hospital in Malaysia. 
    Supported by Johnson & Johnson (Malaysia).
  5. Cost-Effectiveness Analysis of Apixaban for the Treatment of Atrial Fibrillation in Malaysia.
    Supported by Pfizer (Malaysia).
  6. Efficiency Drivers and Barriers Research in ASEAN.
    Supported by Pfizer (Global).
  7. Dapagliflozin Budget Impact Analysis Model & Budget Impact. 
    Supported by AstraZeneca (Malaysia).
  8. Cost Comparison of Diamicron MR & Generic Gliclazide in Preventing Renal Failure in Type 2 Diabetes Mellitus in Malaysia.
    Supported by Servier (Malaysia)
  9. Cost-Effectiveness & Budget Impact Analysis on Non-Valvular Atrial Fibrillation Screening.
    Supported by Pfizer (Malaysia)
  10. Budget Impact Assessment of Secukinumab for Psoriasis, Psoriatic Arthritis & Ankylosing Spondylitis in Malaysia.
    Supported by Novartis (Malaysia)
  11. Healthcare Resource Utilization Analysis of Paliperidone Palmitate in the Treatment of Schizophrenia in the Public Healthcare Sector of Hong Kong.
    Supported by Johnson & Johnson (Hong Kong)

Professional Associations

  1. International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
  2. MySPOR – Malaysian Chapter of ISPOR